Recovery.

A specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination Ebastine (EBA) and Montelukast Sodium (MONTE) in Combined dosage forms. The analysis was carried out using Phenomenex  C18, column (250 mm × 4.6 mm id, 5 µm particle size) with Mobile phase consisting of  Methanol : Phosphate buffer (65:35 v/v) pH 5.0+0.05 was  pumped at a flow rate was 1.0 ml/ min and  Quantification was achieved with photodiode array (PDA) detection at 261 nm over the concentration range of 10 - 50 µg/mL for ebastine & Montelukast Sodium  with mean recovery of 100.32 ± 0.85 % and 100.15 ± 0.94 % for Ebastine and Montelukast Sodium, respectively. These methods were found to be simple, sensitive, accurate, precise and economical and applicable for the simultaneous determination of Ebastine & Montelukast Sodium in combined dosage form.

The manuscript describes validated Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method for the simultaneous estimation of Perindopril Erbumine and Indapamide in combined dosage form. The RP-HPLC separation was achieved on Intersil ODS C18 column (250 mm x 4.6 mm i.d., 5 µm particle size) at 40oC using mobile phase Acetonitrile : Acid Phthalate Buffer (pH 3.0 ± 0.05) (50 :50, v/v) at flow rate 1.0 mL/min. Quantification was achieved with photodiode array (PDA) detection at 240 nm over the concentration range of 10 - 50 µg/mL for Perindopril Erbumine and 3 - 15 µg/mL for Indapamide with mean recovery of 100.09 ± 0.52 % and 100.13 ± 0.09 % for Perindopril Erbumine and Indapamide, respectively. These methods were found to be simple, sensitive, accurate, precise and economical and applicable for the simultaneous determination of Perindopril Erbumine and Indapamide in combined dosage form.